| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c5e77c181522ee1fd44df1ae5ac2196 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 |
| filingDate |
2017-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5395f2f6f363d0fa8fe29691f6566e54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be4ec2214aacf6106edbb96d9670d0dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7907b5286f4f79ac437a63a9bd973ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3da54ad82ff95cb81242d18b3d50accf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e18e77eba566050ca935ab9005dce9fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32e326ade08b12037b9c0076ad7c6afe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6493c3a26a2d32856a969f09f0b810b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0609d6278ad917e67fd4b9a227bf4fe9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a85c04952cf0127862932efa8e22af3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91c27d9869406a430034e0980511ee4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6035d0709c272631f542150047313bcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f21b0f6651b69288e3bca3fb2efef39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed24a02c85bbd3022b6fd206887e0e61 |
| publicationDate |
2020-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-035560-B1 |
| titleOfInvention |
CRYSTALLINE FORMS OF HEMHYDRATE 2 - [(2S) -1-AZABICYCLO [2.2.2] OCT-2-YL] -6- (3-METHYL-1H-PYRAZOL-4-YL) THIENO [3,2-D] PYRIMIDINE- 4 (3H) -HE |
| abstract |
The present invention relates to crystalline form I of hemihydrate 2 - [(2S) -1-azabicyclo [2.2.2] oct-2-yl] -6- (3-methyl-1H-pyrazol-4-yl) thieno [3,2 -d] pyrimidin-4 (3H) -one (compound 1) and / or its tautomers, where compound 1 has a structure to methods of obtaining the crystalline form of compound 1 and / or its tautomers; pharmaceutical compositions; methods for inhibiting cell cycle protein 7 in a mammal; and methods for treating cancer mediated by cell cycle protein 7 in a mammal. |
| priorityDate |
2016-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |